<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00290680</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000454922</org_study_id>
    <secondary_id>MUSC-I065-341-03</secondary_id>
    <secondary_id>MILLENNIUM-100825</secondary_id>
    <nct_id>NCT00290680</nct_id>
  </id_info>
  <brief_title>Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Trial of Bortezomib (VELCADE™) and Celecoxib in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib and celecoxib may stop the growth of tumor cells by blocking some of&#xD;
      the enzymes needed for cell growth. Giving bortezomib together with celecoxib may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib and&#xD;
      celecoxib in treating patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of bortezomib and celecoxib in patients with&#xD;
           advanced solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall pattern of toxicities associated with this combination, including&#xD;
           the emergence of any cumulative toxicities, during multiple courses of this regimen.&#xD;
&#xD;
        -  Describe the response rate and duration of response or disease stability during therapy&#xD;
           in the subset of patients with measurable disease.&#xD;
&#xD;
        -  Assess changes in plasma/serum sphingosine-1-phosphate, ceramide, and other markers of&#xD;
           the apoptotic pathway before and during therapy.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive bortezomib IV on days 1, 4, 8, and 11 or days 1, 8, 15, 22, and 29 and oral&#xD;
      celecoxib twice daily on days 1-21 or 1-42. Courses repeat every 21 or 42 days in the absence&#xD;
      of disease progression or unacceptable toxicity. Patients are evaluated every 2 courses.&#xD;
      Patients achieving complete response (CR) receive 2 additional courses of therapy beyond CR.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of bortezomib and celecoxib until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response and disease progression by RECIST criteria before each course</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologic or cytologic diagnosis of a malignant neoplasm (solid tumor) arising from&#xD;
             any primary site with the exception of bone marrow or lymphoid tissue&#xD;
&#xD;
          -  Recurrent or progressive disease after chemotherapy or radiotherapy&#xD;
&#xD;
               -  Chemotherapy or radiotherapy-naive disease allowed if patient is not a candidate&#xD;
                  for standard treatment either due to comorbidities or lack of willingness to&#xD;
                  undergo standard treatment&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  Bilirubin ≤ 2 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active concurrent invasive malignancy&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2 within the past 14 days&#xD;
&#xD;
          -  No hypersensitivity to bortezomib, boron, mannitol, any of the cyclooxygenase (COX-2)&#xD;
             inhibitors, sulfa drugs, or other nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
&#xD;
          -  No active gastrointestinal (GI) ulcers OR history of GI bleeding resulting from prior&#xD;
             therapy with NSAIDs&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 2 weeks since completion of prior radiotherapy&#xD;
&#xD;
          -  No prior bortezomib&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent chemotherapy, radiotherapy, or anticancer surgery&#xD;
&#xD;
          -  No concurrent immune-enhancing therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew S. Kraft, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustavo Leone</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina, Hollings Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hayslip J, Chaudhary U, Green M, Meyer M, Dunder S, Sherman C, Salzer S, Kraft A, Montero AJ. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer. 2007 Dec 3;7:221.</citation>
    <PMID>18053191</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>February 9, 2006</study_first_submitted>
  <study_first_submitted_qc>February 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2006</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

